CR20110118A - Tratamiento de enfermedades autoinmunes e inflamatorias - Google Patents
Tratamiento de enfermedades autoinmunes e inflamatoriasInfo
- Publication number
- CR20110118A CR20110118A CR20110118A CR20110118A CR20110118A CR 20110118 A CR20110118 A CR 20110118A CR 20110118 A CR20110118 A CR 20110118A CR 20110118 A CR20110118 A CR 20110118A CR 20110118 A CR20110118 A CR 20110118A
- Authority
- CR
- Costa Rica
- Prior art keywords
- treatment
- autoimmune
- inflammatory diseases
- biological activity
- multiple sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona nuevos procedimientos de tratamiento de la esclerosis múltiple y otras enfermedades autoinmunitarias o trastornos inflamatorios, y antagonistas, que incluyen proteínas de unión aisladas para su uso en los nuevos procedimientos. Se proporciona un procedimiento de tratamiento de la esclerosis múltiple que comprende la neutralización de la actividad biológica de la IL-7 mediante la unión a CD127 o a IL-7. Las proteínas de unión aisladas también pueden neutralizar la actividad biológica de la TSLP.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8729408P | 2008-08-08 | 2008-08-08 | |
US16980109P | 2009-04-16 | 2009-04-16 | |
US21862709P | 2009-06-19 | 2009-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20110118A true CR20110118A (es) | 2011-07-28 |
Family
ID=41382165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20110118A CR20110118A (es) | 2008-08-08 | 2011-03-03 | Tratamiento de enfermedades autoinmunes e inflamatorias |
Country Status (23)
Country | Link |
---|---|
US (2) | US20100040616A1 (es) |
EP (1) | EP2318442A1 (es) |
JP (1) | JP2011530533A (es) |
KR (1) | KR20110044777A (es) |
CN (1) | CN102177179A (es) |
AR (1) | AR072985A1 (es) |
AU (1) | AU2009279471A1 (es) |
BR (1) | BRPI0916945A2 (es) |
CA (1) | CA2733432A1 (es) |
CL (1) | CL2011000269A1 (es) |
CO (1) | CO6341640A2 (es) |
CR (1) | CR20110118A (es) |
DO (1) | DOP2011000041A (es) |
EA (1) | EA201100150A1 (es) |
IL (1) | IL211034A0 (es) |
MA (1) | MA32621B1 (es) |
MX (1) | MX2011001477A (es) |
NZ (1) | NZ590994A (es) |
PE (1) | PE20110382A1 (es) |
TW (1) | TW201018482A (es) |
UY (1) | UY32038A (es) |
WO (1) | WO2010017468A1 (es) |
ZA (1) | ZA201100974B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8171134B2 (en) * | 2009-03-18 | 2012-05-01 | At&T Intellectual Property I, L.P. | Methods and apparatus to characterize and predict network health status |
NZ601271A (en) | 2010-01-28 | 2014-09-26 | Glaxo Group Ltd | Cd127 binding proteins |
WO2011100567A1 (en) * | 2010-02-11 | 2011-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic inhibition of granulocyte function in demyelinating disease |
AU2014201648B2 (en) * | 2010-02-24 | 2016-05-12 | Rinat Neuroscience Corp. | Antagonist anti-il-7 receptor antibodies and methods |
US8298535B2 (en) | 2010-02-24 | 2012-10-30 | Rinat Neuroscience Corp. | Anti-IL-7 receptor antibodies |
EP2578232A4 (en) * | 2010-06-02 | 2013-11-20 | Dainippon Sumitomo Pharma Co | TREATMENT FOR AUTOIMMUN DISEASES AND ALLERGIC DISEASES |
US20130295111A1 (en) * | 2010-08-10 | 2013-11-07 | The Scripps Research Institute | Methods and compositions for treating disorders associated with hyperactive immune system |
EP3252076B1 (en) | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Diagnostic use of antibodies against ror-1 protein |
EP2583980A1 (en) | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
FR2988479B1 (fr) * | 2012-03-23 | 2014-12-19 | Hospices Civils Lyon | Procede de determination de la susceptibilite aux infections nosocomiales |
EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
WO2016044189A1 (en) * | 2014-09-15 | 2016-03-24 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists |
WO2016059512A1 (en) | 2014-10-18 | 2016-04-21 | Pfizer Inc. | Anti-il-7r antibody compositions |
EP3268032A1 (en) * | 2015-03-11 | 2018-01-17 | GlaxoSmithKline Intellectual Property Development Limited | Tslp binding proteins |
WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
CA2997809A1 (en) | 2015-10-07 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia |
CN109195987B (zh) | 2016-02-29 | 2022-05-27 | Ose免疫疗法 | 针对IL7受体胞外域的α链的非拮抗性抗体及其在癌症治疗中的应用 |
ES2867900T3 (es) * | 2016-12-09 | 2021-10-21 | Ose Immunotherapeutics | Anticuerpos y polipéptidos dirigidos contra CD127 |
JOP20190243A1 (ar) | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
BR112021014106A2 (pt) | 2019-01-22 | 2021-10-13 | Bristol-Myers Squibb Company | Anticorpos contra subunidade alfa de il-7r e usos dos mesmos |
CN111662381B (zh) * | 2019-03-07 | 2022-06-07 | 瑞阳(苏州)生物科技有限公司 | 人IL-1β蛋白结合分子及其编码基因和应用 |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
US20230073888A1 (en) | 2020-02-13 | 2023-03-09 | Amgen Inc. | Treatment of atopic dermatitis with anti-tslp antibody |
IL295042A (en) | 2020-02-13 | 2022-09-01 | Amgen Inc | Human anti-tslp antibody formulations and methods for treating inflammatory disease |
CA3167975A1 (en) | 2020-02-18 | 2021-08-26 | Amgen, Inc. | Formulations of human anti-tslp antibodies and methods of using the same |
CN116547002A (zh) | 2020-12-02 | 2023-08-04 | 葛兰素史密斯克莱知识产权发展有限公司 | Il-7结合蛋白及其在医学疗法中的用途 |
TW202413441A (zh) | 2022-05-27 | 2024-04-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | TNF-α結合蛋白及IL-7結合蛋白於醫藥治療之用途 |
WO2024163978A2 (en) | 2023-02-02 | 2024-08-08 | Medimmune, Llc | Treatment of chronic rhinosinusitis with anti-tslp antibody |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194375A (en) * | 1989-06-15 | 1993-03-16 | Immunex Corporation | Dna encoding interleukin-7 receptors and methods of use |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
EP0667395A4 (en) * | 1993-06-01 | 1996-07-03 | Toray Industries | MONOCLONAL ANTIBODIES, APPLICATION AND PRODUCTION METHOD. |
US20050054054A1 (en) * | 2002-11-12 | 2005-03-10 | Foss Francine M. | Interleukin-7 molecules with altered biological properties |
US20090130123A1 (en) * | 2004-06-15 | 2009-05-21 | Erol Fikrig | Antibodies to west nile virus polypeptides |
WO2006052660A2 (en) * | 2004-11-04 | 2006-05-18 | Childrens Hospital Los Angeles Research Institute | Il-7 receptor blockade to suppress immunity |
PE20061391A1 (es) * | 2005-02-14 | 2007-01-09 | Wyeth Corp | Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f |
CA2513350A1 (en) * | 2005-03-02 | 2006-09-02 | Sydney West Area Health Service | Treatment for multiple sclerosis |
GB2434578A (en) * | 2006-01-26 | 2007-08-01 | Univ Basel | Transgenic animals |
-
2009
- 2009-08-06 TW TW098126600A patent/TW201018482A/zh unknown
- 2009-08-06 UY UY0001032038A patent/UY32038A/es unknown
- 2009-08-07 US US12/537,705 patent/US20100040616A1/en not_active Abandoned
- 2009-08-07 PE PE2011000140A patent/PE20110382A1/es not_active Application Discontinuation
- 2009-08-07 CN CN2009801397595A patent/CN102177179A/zh not_active Withdrawn
- 2009-08-07 US US13/057,893 patent/US20110287000A1/en not_active Abandoned
- 2009-08-07 AR ARP090103039A patent/AR072985A1/es unknown
- 2009-08-07 JP JP2011522273A patent/JP2011530533A/ja not_active Withdrawn
- 2009-08-07 BR BRPI0916945A patent/BRPI0916945A2/pt not_active IP Right Cessation
- 2009-08-07 EA EA201100150A patent/EA201100150A1/ru unknown
- 2009-08-07 WO PCT/US2009/053136 patent/WO2010017468A1/en active Application Filing
- 2009-08-07 KR KR1020117005442A patent/KR20110044777A/ko not_active Application Discontinuation
- 2009-08-07 MX MX2011001477A patent/MX2011001477A/es unknown
- 2009-08-07 AU AU2009279471A patent/AU2009279471A1/en not_active Abandoned
- 2009-08-07 NZ NZ590994A patent/NZ590994A/xx not_active IP Right Cessation
- 2009-08-07 CA CA2733432A patent/CA2733432A1/en not_active Abandoned
- 2009-08-07 EP EP09791287A patent/EP2318442A1/en not_active Withdrawn
-
2011
- 2011-02-02 DO DO2011000041A patent/DOP2011000041A/es unknown
- 2011-02-03 IL IL211034A patent/IL211034A0/en unknown
- 2011-02-07 ZA ZA2011/00974A patent/ZA201100974B/en unknown
- 2011-02-08 CL CL2011000269A patent/CL2011000269A1/es unknown
- 2011-02-11 CO CO11016609A patent/CO6341640A2/es unknown
- 2011-03-03 CR CR20110118A patent/CR20110118A/es not_active Application Discontinuation
- 2011-03-08 MA MA33682A patent/MA32621B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AU2009279471A1 (en) | 2010-02-11 |
MA32621B1 (fr) | 2011-09-01 |
NZ590994A (en) | 2012-09-28 |
WO2010017468A1 (en) | 2010-02-11 |
KR20110044777A (ko) | 2011-04-29 |
CA2733432A1 (en) | 2010-02-11 |
EP2318442A1 (en) | 2011-05-11 |
MX2011001477A (es) | 2011-03-25 |
AR072985A1 (es) | 2010-10-06 |
PE20110382A1 (es) | 2011-06-27 |
DOP2011000041A (es) | 2011-02-28 |
US20100040616A1 (en) | 2010-02-18 |
TW201018482A (en) | 2010-05-16 |
UY32038A (es) | 2010-03-26 |
CL2011000269A1 (es) | 2012-07-20 |
ZA201100974B (en) | 2012-10-31 |
CN102177179A (zh) | 2011-09-07 |
CO6341640A2 (es) | 2011-11-21 |
EA201100150A1 (ru) | 2011-10-31 |
US20110287000A1 (en) | 2011-11-24 |
IL211034A0 (en) | 2011-04-28 |
JP2011530533A (ja) | 2011-12-22 |
BRPI0916945A2 (pt) | 2015-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20110118A (es) | Tratamiento de enfermedades autoinmunes e inflamatorias | |
ECSP12012211A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
CO6592067A2 (es) | Proteinas de elance a cd 127 | |
ECSP077280A (es) | Moduladores de quinasa de pirrolo-piridina | |
CR20120248A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
EA201370081A1 (ru) | Антитела к cd48 и их применение | |
BR112012009846B8 (pt) | método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige | |
UY32808A (es) | Inmunoglobulinas como dominio variable dual y usos de las mismas | |
CL2014003110A1 (es) | Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano. | |
TW200745109A (en) | Pyrrolo-pyridine kinase modulators | |
EA202090031A3 (ru) | Человеческие антитела против gfr3 и способы их применения | |
EA200901621A1 (ru) | Индукция толерогенного фенотипа у зрелых дендритных клеток | |
ECSP088751A (es) | Anticuerpos contra la il-22 humana y usos para los mismos | |
UA107812C2 (en) | Oktahidropirolo disubstituted [3,4-c] pyrrole receptors as orexin modulators | |
EA201390711A1 (ru) | Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения | |
EA201390669A1 (ru) | Способы и композиции для иммунотерапии заболеваний нервной системы | |
CO6531489A2 (es) | Anticuerpo anti -tslp modificado por técnicas de ingenieria genética | |
BR112014000634A2 (pt) | métodos para tratamento de incontinência associada com atividade sexual | |
CO6630193A2 (es) | Inhibidores de la actividad de la proteína tirosina quinasa seleccionada | |
ECSP13012536A (es) | Composiciones de anticuerpo y métodos de uso | |
UY33662A (es) | Combinaciones que comprenden inhibidores de dhodh e inhibidores de cox | |
ATE489947T1 (de) | Axomadol zur schmerzbehandlung bei arthrose | |
ES2586805T3 (es) | Análogos de péptidos para tratar enfermedades y trastornos | |
ECSP056015A (es) | Anticuerpos contra el receptor de il-21 humano y usos de los mismos | |
CR20110471A (es) | Proteínas de unión específicas y sus usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |